"Introducing CAR-T Central"
Bastion Brands, Australia’s leading healthcare marketing and education specialists have launched CAR-T Central, Australia’s first dedicated medical education website for healthcare professionals to explore the cutting-edge innovations in CAR-T therapy.
With pharmaceutical companies in a global race to introduce CAR-T therapies into the market to treat different types of cancer, Bastion Brands saw the essential need for a resource to help Australian healthcare professionals stay up to date on the latest trends in this new field of study which has only been present in Australia since 2018. The site is supported by industry leaders in the CAR-T therapeutic area.
Speaking of the CAR-T Central announcement, Simon Davies, founder and Chief Executive of Bastion Brands, says, “This website has been 12 months in development, bringing together experts in the field to create an independent source of information on the manufacture of CAR-T cells, the treatment procedure, practical guidance on the clinical use of CAR-T cell therapy, and the latest relevant publications and conference presentations.”
“We are launching to 1,000 haematologists, oncologists and other healthcare professionals specialising in this space and are confident we will be shining a focus on the revolutionary cancer treatment which will only continue to grow as it innovates.”
Associate Professor Emily Blyth (Clinical Lead for immune effector cells at Westmead Hospital), who is the chair of CAR-T Central’s Steering Committee, says, “The launch of CAR-T Central will support frontline clinicians’ education on the new CAR-T cell therapy treatments on offer and being created in Australia. The site provides access to unbiased and well-researched information and will support healthcare professionals to make decisions on appropriate referrals for CAR-T therapy for their patients. It’s also available for quick access for clinical staff who might have contact with patients through their treatment journey.”
About CAR-T Cell Therapy
Chimeric Antigen Receptor (CAR) T-cell therapy is a new form of immunotherapy that utilises genetically engineered T-cells, generally the patient’s own T-cells, to directly target cancer cells.
Currently there are over 17 different CAR antigens being investigated in non-active and ongoing clinical trials with CAR-T for haematological malignancies, with CD19 being the most frequently targeted antigen. There are also active clinical trials of CAR-T to at least 22 antigens for the treatment of solid tumours.
Two therapies are registered for use in Australia, Kymriah® (tisagenlecleucel) for the treatment of acute lymphoblastic leukaemia, and Yescarta® (axicabtagene ciloleucel) and Kymriah® for the treatment of B-cell lymphoma. Initially CAR-T cell therapy was only available at the Peter McCallum Cancer Centre in Victoria, since its introduction the treatment has become available at a number of centres throughout Australia.
M: 0402 425 545
M: 0439 190 700
We are always interested in hearing from great people dedicated to making a career in pharmaceutical communications. If you’re ready to make a positive impact with Bastion Brands, get in touch today.